Click it and Unblock the Notifications
Just In
Don't Miss
-
1:10 Split, 1:1 Bonus; Akshay Kumar-Endorsed Co Which Allotted 5.6 Crore Bonuses, Aims Rs 18,000 Crore Revenue -
Pakistan vs New Zealand Live Streaming: PAK vs NZ Live Telecast in UK, USA and Canada -
Ranam OTT Release Date And Platform: When And Where To Watch Vaibhav Reddy Starrer Movie Online -
Princess Diana's Iconic Dresses And Accessories Will Get Auctioned For Charity, Know The Details Here! -
SCCL Recruitment 2024; Application process, Selection criteria and more -
Mahindra 3XO SUV Latest Teaser Reveals Connected Car Tech: All Details Here -
OnePlus 13 Early Leak Hints at a Revamped Camera Island, and Fast Charging to Remain at 100W -
From Coconut Breaking on Head to Men Dressing as Women: 12 Unique Indian Rituals Explored
Bharat Biotech's Covid nasal vaccine gets approval in India
New Delhi, Nov 28: Bharat Biotech's needle-free intranasal Covid vaccine has been cleared for restricted use in emergencies for those above the age of 18 years.
A press release from the vaccine maker said iNCOVACC, a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised SARS-CoV-2 spike protein, is the world's first intranasal vaccine to receive both primary series and heterologous booster approval.
The vaccine candidate was evaluated in Phases I, II and III clinical trials with successful results and has been specifically formulated to allow intranasal delivery through nasal drops, it said.
The nasal delivery system has been designed and developed to be cost-effective in low- and middle-income countries, Bharat Biotech said.
The vaccine had earlier received approval under Restricted Use in Emergency Situation for ages 18 and above for primary two-dose schedule. Phase-III trials were conducted for safety, immunogenicity in approximately 3,100 subjects, at 14 trial sites across India.
Krishna Ella, Chairman & Managing Director, Bharat Biotech, said: "Despite the lack of demand for COVID vaccines, we continued product development in intranasal vaccines to ensure that we are well-prepared with platform technologies for future infectious diseases... We have also initiated development of variant-specific vaccines for COVID for future preparedness."
iNCOVACC was developed in partnership with Washington University, St Louis, which had designed and developed the recombinant adenoviral vectored construct and evaluated in pre-clinical studies for efficacy.
Rajesh S Gokhale, Secretary, DBT, and Chairperson, BIRAC, said, "The DCGI's approval of Bharat Biotech's intranasal vaccine iNCOVACC (BBV154) to be used as a heterologous booster dose against currently available COVID-19 vaccines is a moment of great pride for our country. This move will further strengthen our collective fight against the pandemic and broaden vaccine coverage."
